The heart-drug developer sent a new signal to biotech investors about what Wall Street is willing to fund in 2026. That is ...

Viking Therapeutics aspires to take market share from both Eli Lilly and Novo Nordisk, and it might succeed.

In interviews as well as a panel at BIO’s annual meeting, investors and life sciences bankers predicted an acceleration in ...

TheFly reported on June 3 that UBS increased its price target on LEGN to $49 from $31 while reiterating a Buy rating on the ...

Intellia's CRISPR pipeline and Omeros's newly approved therapy each bring unique risk and reward profiles, see how their ...

IBB, one of the largest exchange-traded funds focused on biotechnology, manages approximately $8.28 billion in assets and ...

One of the platforms recently attracting global biopharmaceutical companies is the ‘Blood-Brain Barrier (BBB) Shuttle.’ The ...

Big Pharma's patent cliffs are forcing acquirers to hunt for revenue-producing biotech assets before rivals snap them up, and ...

As AI transforms biology, longevity startups are attracting investors, advancing toward clinical milestones, and reshaping ...

VERAXA Biotech (NASDAQ: VRXA) an emerging developer of novel cancer therapies, announced it has expanded its laboratory ...

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.